Glenmark Pharmaceuticals Ltd (GLENMARK) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Glenmark Pharmaceuticals Ltd reported sales of ₹4,018 Cr, operating profit of ₹805 Cr (OPM 20%) and net profit of ₹483 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
GLENMARK quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 3,434 3,388 3,256 3,264 6,047 3,901 3,771 4,018 Expenses 2,832 2,787 2,695 2,684 3,687 3,031 3,008 3,214 Operating Profit 602 600 561 581 2,360 870 763 805 OPM 18% 18% 17% 18% 39% 22% 20% 20% Other Income 39 31 -361 -297 -1,184 -140 -184 66 Interest 48 52 67 58 66 41 43 54 Depreciation 120 123 125 130 141 154 148 173 Profit before tax 473 456 8 96 967 534 388 643 Tax 25% 24% 45% 51% 37% 24% 22% 25% Net Profit 354 348 4 47 610 403 301 483 EPS in Rs 12.55 12.33 0.16 1.66 21.63 14.29 10.68 17.11
GLENMARK profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 12,305 11,583 11,813 13,322 16,983 17,737 Expenses 9,978 9,948 10,618 10,970 12,410 12,940 Operating Profit 2,327 1,635 1,195 2,351 4,572 4,797 OPM 19% 14% 10% 18% 27% 27% Other Income -101 -10 336 -259 -1,805 -1,443 Interest 298 349 516 207 209 204 Depreciation 487 569 582 486 573 617 Profit before tax 1,441 707 434 1,399 1,985 2,533 Tax 31% 47% 430% 25% 31% - Net Profit 994 377 -1,434 1,047 1,362 1,798 EPS in Rs 33.37 10.53 -53.22 37.11 48.26 63.71 Dividend Payout 7% 24% -5% 7% 10% -
GLENMARK balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 28 28 28 - 28 Reserves 9,446 7,820 8,821 - 10,484 Borrowings 4,608 1,231 2,473 - 594 Other Liabilities 5,289 5,279 4,669 - 8,801 Total Liabilities 19,371 14,358 15,991 - 19,907 Fixed Assets 5,422 4,210 4,487 - 5,915 CWIP 1,190 662 835 - 909 Investments 45 790 56 - 42 Other Assets 12,715 8,697 10,613 - 13,041 Total Assets 19,371 14,358 15,991 - 19,907
GLENMARK cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 1,109 625 -265 -828 3,445 Cash from Investing Activity -316 -515 4,387 58 -1,237 Cash from Financing Activity -520 -77 -3,906 787 -2,709 Net Cash Flow 272 32 215 17 -501 Free Cash Flow 320 75 -1,162 -1,576 2,090 CFO/OP 72% 77% 65% -6% 92%
GLENMARK ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 92 115 57 92 107 Inventory Days 208 203 208 254 264 Days Payable 190 172 210 256 288 Cash Conversion Cycle 110 147 56 90 83 Working Capital Days 65 141 -2 44 81 ROCE 16% 10% 12% 19% 40%